2000 Legislation
Print Friendly

HOUSE BILL NO. 680 – Ritalin prescriptn, info to parents

HOUSE BILL NO. 680

View Daily Data Tracking History

View Bill Text

View Statement of Purpose / Fiscal Impact



Text to be added within a bill has been marked with Bold and
Underline. Text to be removed has been marked with
Strikethrough and Italic. How these codes are actually displayed will
vary based on the browser software you are using.

This sentence is marked with bold and underline to show added text.

This sentence is marked with strikethrough and italic, indicating
text to be removed.

Daily Data Tracking History



H0680......................................................by STATE AFFAIRS
RITALIN - Adds to existing law to require that pharmacists who dispense
Ritalin disclose to the person taking possession of the dispensed
prescription, the potentially addictive nature of the drug and other
current medical information on the effects of use of the drug; to require
written verification of the disclosure; to require that a copy of each such
verification be submitted to the Board of Pharmacy; and to direct the Board
of Pharmacy to promulgate rules to ensure that the disclosed information is
provided by the dispensing pharmacist to each person who takes possession
of a prescription and that specified information be placed on the label of
the dispensed prescription.
                                                                        
02/24    House intro - 1st rdg - to printing
02/25    Rpt prt - to Health/Wel

Bill Text


 H0680
                                                                        
                                                                        
  ||||              LEGISLATURE OF THE STATE OF IDAHO             ||||
 Fifty-fifth Legislature                  Second Regular Session - 2000
                                                                        
                                                                        
                              IN THE HOUSE OF REPRESENTATIVES
                                                                        
                                     HOUSE BILL NO. 680
                                                                        
                                 BY STATE AFFAIRS COMMITTEE
                                                                        
  1                                        AN ACT
  2    RELATING TO UNIFORM CONTROLLED SUBSTANCES;  AMENDING  CHAPTER  27,  TITLE  37,
  3        IDAHO  CODE,  BY  THE  ADDITION  OF A NEW SECTION 37-2731A, IDAHO CODE, TO
  4        REQUIRE THAT PHARMACISTS DISPENSING RITALIN SHALL DISCLOSE TO  THE  PERSON
  5        TAKING  POSSESSION OF THE DISPENSED PRESCRIPTION THE POTENTIALLY ADDICTIVE
  6        NATURE OF THE DRUG AND OTHER CURRENT MEDICAL INFORMATION ON THE EFFECTS OF
  7        USE OF THE DRUG, TO REQUIRE WRITTEN VERIFICATION  OF  THE  DISCLOSURE,  TO
  8        REQUIRE THAT A COPY OF EACH SUCH VERIFICATION BE SUBMITTED TO THE BOARD OF
  9        PHARMACY AND TO DIRECT THE BOARD OF PHARMACY TO PROMULGATE RULES TO ENSURE
 10        THAT THE DISCLOSED INFORMATION IS PROVIDED BY THE DISPENSING PHARMACIST TO
 11        EACH  PERSON  WHO  TAKES  POSSESSION  OF A PRESCRIPTION AND THAT SPECIFIED
 12        INFORMATION IS PLACED ON THE LABEL OF THE PRESCRIPTION.
                                                                        
 13    Be It Enacted by the Legislature of the State of Idaho:
                                                                        
 14        SECTION 1.  That Chapter 27, Title 37, Idaho Code, be,  and  the  same  is
 15    hereby  amended by the addition thereto of a NEW SECTION, to be known and des-
 16    ignated as Section 37-2731A, Idaho Code, and to read as follows:
                                                                        
 17        37-2731A.  DISCLOSURE  ON  DISPENSING  RITALIN.  (1)  Any  pharmacist   as
 18    defined  in  section  54-1705(22),  Idaho  Code,  who  dispenses the stimulant
 19    methylphenidate, commonly known as ritalin, shall disclose, at the least,  the
 20    following information:
 21        (a)  As  a  schedule  II drug, it is a controlled uniform substance with a
 22        high potential for abuse, and abuse of the drug may lead to severe psychic
 23        or physical dependence;
 24        (b)  Ritalin is chemically similar to cocaine and methamphetamine,  carry-
 25        ing  with  it a strong potential for increased tolerance levels and addic-
 26        tion;
 27        (c)  Known  side  effects  of  prescriptive  use  of  the   drug   include
 28        tachycardia,  dizziness,  insomnia,  depression, abdominal pain, anorexia,
 29        loss of appetite, dry mouth, and suppression of growth has been associated
 30        with long-term use;
 31        (d)  Ingesting the tablet by any means other than swallowing can result in
 32        severe reactions or complications such as blood clots, skin  and  circula-
 33        tory problems and even death;
 34        (e)  Symptoms  of  overdose may include agitation, confusion, convulsions,
 35        delirium, dryness of mucous membranes, enlarging of the pupil of the  eye,
 36        exaggerated  feeling  of  elation,  extremely  elevated  body temperature,
 37        flushing, hallucinations, headache,  high  blood  pressure,  irregular  or
 38        rapid heartbeat, muscle twitching, sweating, tremors or vomiting;
 39        (f)  No  person  who  takes  ritalin after the age of twelve (12) years is
 40        eligible for military service; and
 41        (g)  Distribution of the medication  to  any  other  person  is  a  felony
 42        offense in Idaho and is also a federal offense.
 43        (2)  On  a  form  provided  by or acceptable to the board of pharmacy, the
                                                                        
                                           2
                                                                        
  1    pharmacist shall obtain the signature of each person who takes possession of a
  2    prescription verifying that the pharmacist disclosed the information  required
  3    in subsection (1) of this section.
  4        (3)  A  copy  of each signed verification of disclosure shall be submitted
  5    to the board of pharmacy within thirty (30) days of  the  signing.  Such  com-
  6    pleted forms may also be submitted in electronic form.
  7        (4)  The  board  is  authorized and directed to promulgate rules to ensure
  8    that  the information in subsection (1) of this section  is  provided  by  the
  9    dispensing  pharmacist  to each person who takes possession of a prescription,
 10    and the board shall further provide for notation to be placed on the label  of
 11    the dispensed prescription which states, at a minimum, that:
 12        (a)  Ingestion  of  the contents by a person thirteen (13) years of age or
 13        older shall render such person ineligible for military service; and
 14        (b)  It is a federal felony offense and a felony in the state of Idaho  to
 15        distribute  this medication to any person other than the person to whom it
 16        has been prescribed.
 17    In addition, the board is responsible for ensuring that the  information  pro-
 18    vided by the dispensing pharmacist is consistent with the most current medical
 19    findings.

Statement of Purpose / Fiscal Impact


     
     
                STATEMENT OF PURPOSE 
                     RS 09314C2 
     
     The purpose of this legislation is to add additional information to the labeling of
     Methylphenidate by a pharmacy.
     
     
      
                    FISCAL IMPACT
     
     No fiscal impact to the General Fund. 
     
     
     
     
     
     
     
     
     Contact 
     Name: Rep. John L. Campbell
     Phone: 332-1000
     
      
     
                                                  STATEMENT OF PURPOSE/FISCAL NOTE                              H 680